Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections, a Triple Arm Study

Trial Profile

Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections, a Triple Arm Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Nepafenac (Primary)
  • Indications Injection site pain; Ocular pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2018 Planned End Date changed from 1 Feb 2018 to 28 Feb 2018.
    • 08 Feb 2018 Planned primary completion date changed from 30 Jan 2018 to 15 Feb 2018.
    • 25 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top